DexCom, Inc. (DXCM)

NASDAQ · Health Care · market cap 28.45B

Share price

$87.93

At the last nightly close

Intrinsic value

$35.33

Range $35.33 – $38.86 — the conservative figure is the low end.

Margin of safety

-59.8%

($35.33 − $87.93) ÷ $87.93

EV / EBIT

n/a

Not ranked: negative ebit.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-08-29.

Key metrics

Price / earnings34.8
Price / book12.7
EV / EBITDA23.1
FCF / EVn/a
Return on equity+38.5%
Return on assets+10.3%
Debt / equity0.53
Gross margin+62.5%

Market position

52-week high$92.34
52-week low$54.84
From 52-week high-4.8%
RSI (14)54.9
200-day moving average$74.89

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY4.66B911.8M836.3M2.141.08B
2024-FY4.03B600.0M576.2M1.46630.7M
2023-FY3.62B597.7M541.5M1.40511.9M
2022-FY2.91B391.2M341.2M0.88304.7M
2021-FY2.45B265.8M216.9M0.5353.3M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedOctober 29, 2026
Consensus EPS estimate0.67

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on DXCM.

Run the board on DXCM

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.